Who are Pertuzumab (Perjeta®)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): pertuzumab (P), SHR-A1811 Injection ； Pertuzumab Injection, Pertuzumab IV, Pertuzumab Injection, EU-Perjeta®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pertuzumab-perjeta.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pertuzumab (Perjeta®) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pertuzumab (Perjeta®) (Pertuzumab (Perjeta®)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2 inhibitor monoclonal antibody. Area: Oncology.

phase 3 HER2 inhibitor monoclonal antibody HER2 (Human Epidermal Growth Factor Receptor 2) Oncology Biologic Live · refreshed every 30 min

Target snapshot

Pertuzumab (Perjeta®) (Pertuzumab (Perjeta®)) — Zydus Lifesciences Limited. Pertuzumab is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER receptors, preventing cancer cell growth signaling.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Pertuzumab (Perjeta®) TARGET	Pertuzumab (Perjeta®)	Zydus Lifesciences Limited	phase 3	HER2 inhibitor monoclonal antibody	HER2 (Human Epidermal Growth Factor Receptor 2)
pertuzumab (P)	pertuzumab (P)	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	marketed	HER2 inhibitor monoclonal antibody	HER2 (human epidermal growth factor receptor 2)
SHR-A1811 Injection ； Pertuzumab Injection	SHR-A1811 Injection ； Pertuzumab Injection	Jiangsu HengRui Medicine Co., Ltd.	phase 3	HER2 inhibitor monoclonal antibody	HER2 (human epidermal growth factor receptor 2)
Pertuzumab IV	Pertuzumab IV	Hoffmann-La Roche	phase 3	HER2 inhibitor monoclonal antibody	HER2 (human epidermal growth factor receptor 2)
Pertuzumab Injection	Pertuzumab Injection	RemeGen Co., Ltd.	phase 3	HER2 inhibitor monoclonal antibody	HER2 (Human Epidermal Growth Factor Receptor 2)
EU-Perjeta®	EU-Perjeta®	Shanghai Henlius Biotech	phase 3	HER2 inhibitor monoclonal antibody	HER2 (Human Epidermal Growth Factor Receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2 inhibitor monoclonal antibody class)

Hoffmann-La Roche · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
RemeGen Co., Ltd. · 1 drug in this class
Shanghai Henlius Biotech · 1 drug in this class
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class
Zydus Lifesciences Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pertuzumab (Perjeta®) — Competitive Intelligence Brief. https://druglandscape.com/ci/pertuzumab-perjeta. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing